Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

N-glycoproteomics on BC and normal control cell lines

ABSTRACT: Comprehensive membrane N-glycoproteomics using human breast cancer cell line pairs, Hs578T and Hs578Bst.

ORGANISM(S): Homo Sapiens (human)

SUBMITTER: Daisuke Takakura

PROVIDER: PXD040130 | JPOST Repository | Fri Feb 16 00:00:00 GMT 2024

REPOSITORIES: jPOST

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	Breast%20Cancer_578T_membrane_glycopeptide_1.raw	Raw
	Breast%20Cancer_578T_membrane_glycopeptide_2.raw	Raw
	Breast%20Cancer_578T_membrane_glycopeptide_3.raw	Raw
	Breast%20Cancer_578_glycopeptide_Byonic_Quan.xlsx	Xlsx
	Breast%20Normal_578Bst_membrane_glycopeptide_1.raw	Raw

Items per page:

1 - 5 of 7

Publications

Comprehensive Membrane N-Glycoproteomics Using Human Breast Cancer Cell Line Pairs.

Takakura Daisuke D Yoshida Haruka H Ohashi Shoko S Kawasaki Nana N

Mass spectrometry (Tokyo, Japan) 20230411 1

Aberrant glycosylation of membrane proteins is a hallmark of cancer and a useful molecular marker for the diagnosis of breast cancer (BC). However, the molecular mechanisms by which altered glycosylation affects the malignant transformations associated with BC are poorly understood. Accordingly, we performed comparative membrane N-glycoproteomics using the human BC cell line pair, Hs578T, and its syngeneic normal cell line, Hs578Bst. A total of 359 N-glycoforms derived from 113 pro ...[more]

PMID: 37250596

Similar Datasets

Quantitative glycoproteomics reveals cellular substrate selectivity of the endoplasmic reticulum protein quality control sensors UGGT1 and UGGT2

Project description:The protein quality control sensors UDP-glucose: glycoprotein glucosyltransferase (UGGT) 1 and 2 are proposed to act as gatekeepers of the early secretory pathway. They initiate rebinding to the carbohydrate-dependent chaperones calnexin and calreticulin that associate with proteins possessing monoglucosylated glycans. The UGGTs control glycoprotein exit from the endoplasmic reticulum (ER) for trafficking to the Golgi or ER retention to provide additional folding opportunities. A quantitative glycoproteomics strategy was used to identify cellular glycoproteins modified by the UGGTs at endogenous levels and delineate the specificities of UGGT1 and UGGT2. UGGT substrates were comprised of seventy-one mainly large multidomain and heavily glycosylated proteins when compared to the general N-glycome. UGGT1 was the dominant glucosyltransferase with a preference towards large plasma membrane proteins whereas UGGT2 favored the modification of smaller, soluble lysosomal proteins. This study provides insight into the cellular secretory load that utilizes multiple rounds of carbohydrate-dependent chaperone intervention for proper maturation.

2020-11-28 | GSE162262 | GEO

Phosphoproteomics and glycoproteomics of small cell lung cancer

Project description:We collected 12 pairs of SCLC tumors and NATs for phosphoproteomics, as well as 10 pairs of SCLC tumors and NATs for glycoproteomics.

| PXD078456 |

Plasma N-Glycoproteomics for BMI-discordant monozygotic twin pairs

Project description:The aim of the project was to identify altered plasma proteins and altered plasma N-glycopeptides from monozygotic twin pairs who are discordant for body weight. We performed targeted quantitative N-glycoproteomics from plasma samples from 48 twin pairs (n = 96 individuals).

2025-05-06 | PXD041384 | Pride

Glycoproteomics of breast cancer cell lines

Project description:Breast cancer is the most common cancer among women. However, the use of immune checkpoint inhibitors, that have revolutionized treatment of multiple cancers, unfortunately remain largely ineffective in most breast cancer patients. Here, we report the most comprehensive glycoproteome map in breast tumor cells, pointing to a key role of sialic acid modifications in mammary cancer. Genetic and pharmacologic inhibition of sialylation repolarizes the tumor microenvironment, leading to a reduction in myeloid-derived suppressor cells and a significant increase in Tcf7+ memory and CD8+ effector T cells. Mechanistically, sialylation controls cell surface expression of MHC class I and PD-1-ligand on the tumor cells. Functionally, in vivo interference with sialylation on breast cancer cells licenses CD8+ T cells to effectively kill the tumors. In multiple immunotherapy-resistant breast tumor models, we also show that the abrogation of sialylation sensitizes to anti-PD-1 immune checkpoint therapy. We further demonstrate that hyper-sialylation occurs in over half of human breast cancers tested and correlates with poor T cell infiltration. Our results establish sialylation as a central immunoregulator in breast cancer, orchestrating multiple pathways of immune evasion. Targeting tumor sialylation licenses immunologically inert mammary tumors to be efficiently eliminated by anti-cancer immunity and sensitizes to immune checkpoint therapy.

2026-05-05 | PXD067987 | Pride

Plasma N-Glycoproteomics for BMI-discordant monozygotic twin pairs

2025-05-06 | PXD041584 | Pride

Quantitative glycoproteomics reveals cellular substrate selectivity of the endoplasmic reticulum protein quality control sensors UGGT1 and UGGT2

Project description:Quantitative glycoproteomics reveals cellular substrate selectivity of the endoplasmic reticulum protein quality control sensors UGGT1 and UGGT2

| PRJNA681212 | ENA

Re-analysis of glycoproteomics data with MSFragger-Glyco

Project description:Reanalysis of submissions PXD011533 and PXD009476 using MSFragger-Glyco mode. Processed MSFragger results files (pepXML) and PSM tables (psm.tsv) supporting MSFragger-Glyco manuscript (Fast and Comprehensive N- and O-glycoproteomics analysis with MSFragger-Glyco. Recent advances in methods for enrichment and mass spectrometric analysis of intact glycopeptides have produced large-scale glycoproteomics datasets, but interpreting this data remains challenging. We present MSFragger-Glyco, aa new glycoproteomics mode of the MSFragger search engine, called MSFragger-Glyco, for fast and sensitive identification of N- and O-linked glycopeptides and open glycan searches. Reanalysis of recent N-glycoproteomics data resulted in annotation of 80% more glycopeptide-spectrum matches (glycoPSMs) than previously reported. In published O-glycoproteomics data, our method more than doubled the number of glycoPSMs annotated when searching the same glycans as the original search and yielded 4-6-fold increases when expanding searches to include additional glycan compositions and other modifications. Expanded searches also revealed many sulfated and complex glycans that remained hidden to the original search.

2020-10-06 | PXD021196 | Pride

Small RNAs subcellular distribution in breast cancer and normal cell lines

Project description:We detect the small RNAs subcellular distribution in breast cancer cell lines MCF-7 and MDA-MB-231, and normal cell line MCF-10A.

2009-06-16 | GSE15937 | GEO

GproDIA enables intact glycopeptide characterization using data‐independent acquisition glycoproteomics with comprehensive statistical control

Project description:Large-scale profiling of intact glycopeptides is critical but challenging in glycoproteomics. Data independent acquisition (DIA) is an emerging technology with deep proteome coverage and accurate quantitative capability in proteomic studies, but is still in the early stage of development in the field of glycoproteomics. We propose GlycoSWATH, a pipeline for the proteome-wide characterization of intact glycopeptides from DIA data with comprehensive statistical control by a 2-dimentional false discovery rate approach and a glycoform inference algorithm, enabling accurate identification of intact glycopeptide using wide isolation windows. We further adapt a semi-empirical spectrum prediction strategy to expand the coverage of spectral libraries of glycopeptides. We benchmark our method for N-glycopeptide profiling on DIA data of yeast and human serum samples, demonstrating that DIA with GlycoSWATH outperforms the state-of-the-art DDA method for glycoproteomics in terms of capacity and data completeness of identification, as well as accuracy and precision of quantification. We expect that this work can provide a powerful tool for glycoproteomic studies.

2021-06-22 | PXD023980 |

Genome wide DNA methylation profiling of normal breast, normal adjacent and breast cancer tissue

Project description:The Illumina Infinium 450k Human DNA methylation Beadchip was used to obtain DNA methylation profiles across approximately 480,000 CpGs in a total of 407 samples, including 50 normal samples from healthy women, 42 matched normal-adjacent breast cancer pairs (84 samples), 263 unmatched breast cancers, 7 normal samples from BRCA1 carriers and 4 BRCA1 breast cancers. ***WARNING: incomplete metadata supplied for this study***

2015-06-18 | GSE69914 | GEO